APDN

APDN

Applied DNA Sciences specializes in molecular technologies that provide product authentication and supply chain security.
The company is a leader in leveraging DNA-based marking to combat counterfeiting and ensure traceability across various industries.

$0.00 +0.00 (+0.00%)

Updated: 2025年12月23日 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model ✓ Updated Daily

Investment Opinion: Is APDN Worth Buying?

Based on the provided analysis, APDN presents substantial and fundamental challenges that make it unsuitable for investment at this time.

Analysis Summary:

The company is experiencing a severe operational downturn, highlighted by a drastic 70% quarterly revenue decline and gross margins collapsing to 1.7%. This signifies a critical failure in its business model or market position. Financially, while short-term liquidity appears adequate, this is overshadowed by deeply negative cash flows and returns on equity and assets, indicating poor capital allocation and an unsustainable burn rate. The complete lack of standard valuation metrics and peer comparables further underscores its speculative and high-risk nature.

Recommendation:

Do Not Buy. APDN exhibits multiple red flags, including rapidly deteriorating fundamentals, negative profitability, and a high degree of speculative risk due to illiquidity and missing data. The company's current trajectory suggests significant financial distress, and the absence of standard valuation anchors makes it impossible to assess any potential upside. Investors should consider more stable and transparent opportunities.

*Note: This is not investment advice, for reference only.*

CTA Banner

12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Of course. Here is a 12-month outlook for APDN based on the analysis provided.

12-Month Outlook for APDN

APDN's outlook for the next 12 months is critically challenged. The primary catalyst for any positive movement would be a successful, drastic restructuring plan to address the 70% revenue decline and restore gross margins, but evidence of such a plan is not indicated. The most significant risks are the company's apparent financial distress, unsustainable cash burn, and the potential for illiquidity or further devaluation. Given the complete absence of analyst targets and the severe deterioration in fundamentals, establishing a credible target price range is not feasible, with the risk of significant loss of capital being high. The path of least resistance appears to be continued operational and share price decline.

Wall Street Consensus

Most Wall Street analysts are optimistic about APDN's outlook over the next 12 months, with consensus target price around $0.00, indicating expectations for further upside potential.

Average Target
$0.00
Based on 0 analysts
Implied Upside
+0%
vs. Current Price
Analyst Coverage
0
Covering this stock
Price Range
$0 - $0
Analyst target range
Buy Buy
0 (0%)
Hold Hold
0 (0%)
Sell Sell
0 (0%)

Bull vs Bear Case for APDN

Overall, APDN has investment merit but also faces multiple challenges. Here are the key factors to consider before investing in this stock.

Bullish Bullish
  • Major capital infusion: Raised up to $58 million to fund new digital asset treasury strategy.
  • Strategic pivot execution: Company actively building BNB treasury with over $17 million in holdings.
  • Positive pre-market momentum: Stock showed significant pre-market trading activity and a recent 31% jump.
  • Rebranding for new focus: Ticker change to BNBX reflects commitment to digital asset strategy.
Bearish Bearish
  • High-risk strategic shift: Pivoting from biotech to crypto assets carries significant execution risks.
  • Market volatility exposure: New strategy makes company highly susceptible to cryptocurrency price swings.
  • Core business uncertainty: Focus shift raises questions about future of original nucleic acid business.
  • Sympathy move vulnerability: Stock recently fell over 9% in sympathy with other tech sector losses.
Reward Banner

APDN Technical Analysis

APDN's price performance cannot be assessed with the provided data due to multiple missing key metrics.

Critical performance indicators including current price, short-term changes, and benchmark comparisons are unavailable, preventing any meaningful analysis of recent trends or relative performance versus the market. The absence of 52-week range data and volatility measures further precludes determining the stock's current position or risk characteristics.

Without fundamental pricing information or historical performance data, no conclusion can be drawn regarding whether APDN is overbought, oversold, or trading within its normal range. A complete dataset would be required to perform a proper technical analysis of this security.

📊 Beta
1.00
1.00x market volatility
📉 Max Drawdown
0.0%
Largest drop in past year
📈 52-Week Range
$0-$0
Price range over past year
💹 1-Year Return
+0.0%
Total return over past year
Period APDN Return S&P 500

APDN Fundamental Analysis

Revenue & Profitability

APDN demonstrates concerning revenue contraction and profitability challenges. Quarterly revenue declined significantly from $983,374 to $304,393, while gross profit margins deteriorated dramatically from 37.7% to just 1.7%, indicating severe pricing pressure or cost inefficiencies. The company reported substantial operating losses with negative operating margins of -12.1% in Q3, reflecting an inability to control expenses relative to declining revenue.

Financial Health

The company maintains adequate short-term liquidity with current and quick ratios above 2.5, though its cash flow position is precarious with a deeply negative cash flow to debt ratio of -8.4. While debt levels appear manageable with low debt-to-equity and capitalization ratios near 4%, the negative operating cash flow per share of -$4.92 raises sustainability concerns. The negative cash conversion cycle of -24 days suggests APDN is collecting receivables faster than paying suppliers, which may provide temporary working capital relief but isn't sustainable long-term.

Operational Efficiency

APDN shows severe operational inefficiencies with return on equity at -54.3% and return on assets at -39.7%, indicating poor capital allocation. Asset turnover of just 0.03 reflects extremely weak revenue generation relative to the asset base. The extended operating cycle of 161 days and low inventory turnover of 0.88 suggest sluggish inventory management, while high days sales outstanding of 59 days points to potential collection issues despite the favorable cash conversion cycle positioning.

Quarterly Revenue
N/A
Latest Quarter
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A%
Latest Quarter
Free Cash Flow
N/A
Last 12 Months

Revenue & Net Income Trend (2 Years)

See if the company is still growing or starting to slow down

Revenue Breakdown by Segment

Understand if it's a single-product story or multiple business lines

RockFlow Bobby - Your 24/7 AI Investment Partner

Get real-time data and AI-driven investment insights to make smarter investment decisions

Sign up now and get Tesla stock!

Valuation Analysis: Is APDN Overvalued?

Valuation Level: APDN lacks meaningful valuation metrics as none of the standard ratios (PE, PB, PS, EV/EBITDA) are available, which indicates the company either has negative earnings, book value, or insufficient operational scale for traditional valuation assessment. This absence of fundamental valuation anchors makes it impossible to determine whether the stock is overvalued or undervalued using conventional financial metrics. The lack of measurable profitability or asset-based valuation suggests significant investment risk and speculative characteristics.

Peer Comparison: Without available industry average data, meaningful peer comparison cannot be conducted to benchmark APDN's valuation against sector standards. This data gap prevents assessment of whether the company trades at a premium or discount relative to industry norms. The absence of comparable industry metrics further complicates investment analysis and suggests APDN may operate in a niche segment or face unique circumstances that limit conventional benchmarking approaches.

Current PE
N/A×
TTM
vs. Historical
N/A
vs. Industry Avg
N/A
Industry PE ~ N/A×
EV/EBITDA
N/A×
Enterprise Value Multiple

Investment Risks

Of course. Here is a risk analysis for APDN based on the limited data provided.

Volatility Risk A definitive analysis of APDN's volatility risk is not possible due to the lack of Beta and maximum drawdown data. The absence of a Beta suggests the stock may have extremely low liquidity, be a new listing, or have a trading history too erratic for a reliable correlation to the broader market to be established. Similarly, without a maximum drawdown figure, it is impossible to quantify the peak-to-trough decline the stock has experienced, which is a critical measure of its historical price risk.

Other Risks The primary risk indicated by the provided data is a severe lack of transparency and potentially extreme illiquidity. The fact that key metrics like short interest are not available often points to a stock with very low trading volume and minimal analyst coverage. This illiquidity itself is a major risk, as it can lead to high bid-ask spreads and make it difficult to buy or sell shares without significantly impacting the stock price.

FAQs

Is APDN a good stock to buy?

Bearish - This stock carries exceptionally high risk. The company is undergoing a radical pivot from biotech to cryptocurrency assets, creating major execution uncertainty amid severely deteriorating fundamentals including collapsing revenue and negative cash flow. Given the extreme volatility and speculative nature of this transition, only highly risk-tolerant speculators should consider this, not traditional investors.

Is APDN stock overvalued or undervalued?

Based on the available data, APDN appears significantly overvalued due to a complete lack of fundamental justification for its price.

The stock lacks standard valuation metrics (PE, PB, PS) because it has no earnings, a weak asset base, and minimal revenue, making any positive valuation speculative. Its fundamentals are alarming, with rapidly declining revenue, a near-eradication of gross profit (1.7% margin), and deeply negative returns on equity and assets (-54.3% and -39.7%, respectively). Given the company's severe operational challenges and lack of profitability, its current market price is not supported by its financial performance, indicating a high likelihood of overvaluation.

What are the main risks of holding APDN?

Based on the provided data, here are the key risks of holding APDN:

1. Severe Profitability and Revenue Risk: The company is experiencing a drastic decline in revenue and gross margins, leading to substantial operating losses that threaten its ability to continue as a going concern. 2. Extreme Illiquidity and Information Risk: The stock suffers from a severe lack of trading activity and analyst coverage, indicated by numerous missing data points, which creates high transaction costs and makes it difficult to accurately value or efficiently trade the shares. 3. Critical Operational Inefficiency Risk: Extremely poor returns on equity and assets, coupled with very low asset turnover, demonstrate fundamental flaws in the company's business model and its ability to generate value from its capital. 4. Cash Flow Sustainability Risk: Deeply negative operating cash flow reveals that the company's core operations are burning cash, which is unsustainable over the long term despite currently appearing to have adequate cash-on-hand.

What is the price forecast for APDN in 2026?

Of course. Given the critical fundamental challenges facing Applied DNA Sciences (APDN), here is a strategic forecast.

***

APDN Stock Forecast & Outlook through 2026

1. Target Price / Outlook: Establishing a specific target price is exceptionally high-risk due to the company's severe financial distress. The most probable scenarios are: * Base Case (Downside): Continued operational decline leading to potential bankruptcy or dissolution, rendering the stock effectively worthless. * Bull Case (Highly Speculative): A successful, drastic corporate restructuring or a major, unforeseen commercial partnership that reverses the revenue collapse. Even in this unlikely scenario, any recovery toward the $1.00 level would be a significant achievement.

2. Key Growth Drivers (Potential Catalysts for Change): * Successful Restructuring: A credible and immediately executable plan to drastically cut costs, refocus the business on viable product lines, and stabilize the cash burn. * Major Contract Win: Securing a large-scale, recurring revenue contract that can offset the 70% revenue decline and demonstrate commercial viability. * Strategic Acquisition or Partnership: Being acquired by or forming a strategic alliance with a larger, well-capitalized company to provide financial stability and market access.

3. Main Assumptions: * The current trends of severe revenue decline and negative gross margins continue without immediate, radical intervention. * The company's cash reserves are insufficient to fund operations for an extended period without additional dilutive financing. * No major, positive shift in market conditions or technology adoption occurs to organically rescue the business.

4. Uncertainty & Risk: This forecast carries extreme uncertainty. The company's financials indicate a high probability of failure. The bull case is entirely dependent on a transformative corporate event for which there is currently no public evidence. Investing in APDN at this stage is highly speculative and should be considered only by those who can tolerate a total loss of capital.